carcinoma in-situ

临床试验

计划入组 74 人 · 首次发布于 2018 年 6 月 1 日

进行中（未招募）

NCT02872025

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

计划入组 42 人 · 首次发布于 2016 年 8 月 18 日

已完成

NCT03148015

Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)

计划入组 30 人 · 首次发布于 2017 年 5 月 10 日

药物

查看全部 2816 →

Biotech

Approved

Nadofaragene firadenovec-vncg(Adstiladrin)

相关疾病：High risk BCG-unresponsive non-muscle invasive bladder cancer

in situ autologous dendritic cell therapy (liver cancer)

hepatocellular carcinoma program

机构

查看全部 1379 →

In His Image

United States

Partners In Health

United States

German University in Cairo

Germany

资讯

查看全部 40786 →

2年前

Cretostimogene Shows High Complete Response Rate in BCG-Unresponsive Bladder Cancer

9个月前

EMA Grants Conditional Marketing Authorization for ImmunityBio's ANKTIVA in Bladder Cancer

10个月前

临床试验

MRI in Ductal Carcinoma in Situ (DCIS)

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)

药物

Nadofaragene firadenovec-vncg(Adstiladrin)

in situ autologous dendritic cell therapy (liver cancer)

hepatocellular carcinoma program

机构

In His Image

Partners In Health

German University in Cairo

资讯

Cretostimogene Shows High Complete Response Rate in BCG-Unresponsive Bladder Cancer

EMA Grants Conditional Marketing Authorization for ImmunityBio's ANKTIVA in Bladder Cancer

enGene Holdings Reports 63% Complete Response Rate in Phase 2 Bladder Cancer Gene Therapy Trial